Rare Disease Treatment Funding News in India

Rare Disease Treatment Funding News: What Changed?

For families dealing with a rare disease, the diagnosis is often only the beginning of the problem. The next question can be painfully practical: Who will pay for treatment?

Some rare diseases require specialised medicines, enzyme replacement therapy, gene-based treatment or other long-term care that can cost far more than an average household can manage. India's policy response has expanded over the years, but access remains uneven.

The latest developments in 2026 show two different sides of the issue. There is more government support and greater attention to affordability, but funding availability, eligibility, paperwork and treatment capacity can still determine whether a patient actually receives help.

What is the latest rare disease funding update?

The biggest recent change came with the Union Budget 2026-27. The government proposed adding seven more rare diseases to the list eligible for customs-duty exemption on personal imports of medicines and Food for Special Medical Purposes used in their treatment. The proposal is aimed at reducing the import-related cost burden for affected families.

This follows earlier customs relief. In 2023, the government announced full exemption from basic customs duty for drugs and specialised foods imported for personal treatment of rare diseases covered under the National Policy for Rare Diseases.

The distinction matters. A customs-duty exemption is not the same as free treatment. It can reduce the landed cost of an imported product, but families may still face substantial expenses for the medicine, hospital care, testing, travel and long-term follow-up.

For background on the wider problem of expensive medicines, readers can also see DOCTAR's guides on [affording medicines in India]affording medicines in India and [prescription medicine discounts]prescription medicine discounts.

How much government support is available?

The National Policy for Rare Diseases has created a formal route for financial and medical assistance. A March 2026 government response said the policy provides financial and medical support of up to ₹50 lakh per patient for treatment of identified rare diseases through designated Centres of Excellence.

That figure should not be read as a guaranteed ₹50 lakh payment to every patient. Assistance depends on the disease, eligibility, treatment plan, applicable rules and the designated treatment pathway.

Government information has previously stated that patients seeking assistance can approach a notified Centre of Excellence to register and begin the process. The government has also identified Centres of Excellence for diagnosis, prevention and treatment of rare diseases.

Families researching the cost of a particular therapy may find DOCTAR's [Spinraza cost and assistance guide]Spinraza cost and assistance guide useful as a general example of the financial questions involved in rare-disease treatment.

Why funding does not always mean immediate treatment

A policy can exist on paper while the patient still waits. This is one of the less visible parts of rare-disease care.

Funding may have to move through government departments, designated hospitals and treatment programmes. The medicine itself may also need regulatory clearance, import arrangements, specialist administration or monitoring.

A recent report highlighted concerns about unspent allocations at some Centres of Excellence alongside a decline in fresh allocations for rare-disease treatment. Those figures come from media reporting and should be interpreted carefully, because budget allocation, fund release and actual treatment expenditure are different measures.

In clinical practice, this is often missed because the medical decision and the financial-access decision happen at the same time. A specialist may know what treatment is appropriate, but the family still needs someone to explain how that treatment can realistically be financed.

What other funding routes can families explore?

Government support is only one part of the picture. Depending on the disease and treatment, families may need to explore several routes at once.

Patient-assistance programmes run by pharmaceutical companies can sometimes provide discounted or subsidised medicines to eligible patients. DOCTAR's [Soliris cost and assistance guide]Soliris cost and assistance guide and [Ultomiris financial assistance guide]Ultomiris financial assistance guide explain how manufacturer support can fit into the broader treatment-cost picture.

Similar financial-assistance information is available in DOCTAR's guides to [Haegarda treatment costs]Haegarda treatment costs, [Epidiolex costs and assistance]Epidiolex costs and assistance and [Xyrem financial assistance]Xyrem financial assistance.


What should families do after a rare disease diagnosis?

Do not wait until the treatment bill arrives to ask about funding.

Ask the treating specialist which Centre of Excellence or authorised facility should handle the case. Request a written treatment estimate, including medicine, administration, investigations and follow-up costs.

Keep copies of the diagnosis, genetic or laboratory reports, prescriptions, hospital estimates, identity documents and financial-assistance applications. A hospital social worker, patient-support team or financial counsellor may be able to help with the paperwork.

The government also operates a Rare Diseases digital portal for crowdfunding and voluntary donations, designed to allow individual and institutional donors to support eligible patients through treating institutions.

Crowdfunding should be treated as one possible source of support, not as a substitute for government assistance or medical advice.